“Unravelling the dark matter of infectious diseases, environmental and genetic factors tipping the balance towards NCDs” (“ID-DarkMatter-NCD”)

Synopsis:

Use of retrospective data for clinical research.

Immune system-related non-communicable diseases (referred to in the source documentation as ENI-TI) are characterised by autoimmune or inflammatory phenotypes and include conditions such as post-Covid-19 condition (PCC), multiple sclerosis (MS), myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and inflammatory bowel disease (IBD). The objectives are to: 1) identify immune events (IEs) that trigger ENI-TIs, and 2) disentangle the environmental and genetic factors that influence the transition from IEs to ENI-TIs by combining multi-omics approaches and innovative technologies for personalised genotyping of adaptive immune receptor genes.

Participating institutions:

  • Medizinische Universitaet Wien, [MUW]
  • University Medical Center Groningen [UMCG]
  • EUTEMA Research Services GmbH [EUT-RS]
  • Sorbonne Université [SU]
  • Academisch Ziekenhuis Leiden [LUMC]
  • Universitatsklinikum Schleswig-Holstein [UKSH]
  • Szegedi Biologiai Kutatokozpont [BRC]
  • Karolinska Institutet [KI]
  • Vall d’Hebron University Hospital Foundation – Research Institute [VHIR]
  • Assistance Publique Hopitaux de París [APHP]

Data origin:

IMID Biobank of Vall d’Hebron University Hospital Biobank and the National DNA Bank.

Clinical cohorts.

Retrospective. A population-scale cohort (“LifeLines”). In LifeLines, samples from more than 150,000 healthy individuals were collected longitudinally over a period exceeding 15 years. Over time, some individuals developed ENI-TIs, which were recorded during follow-up. Within ID-DarkMatter-NCD, samples from these patients collected prior to disease onset are accessed in order to identify pre-diagnostic markers of subclinical differences that precede and predict disease onset.

The VHIR group will contribute (together with other European consortium partners) DNA and plasma samples from patients in immune-mediated disease (IMID) cohorts, the associated genetic and omics analyses linked to the project, expert interpretation of the results, and dissemination through Open Access publications.

Subscribe to our newsletters and be a part of Vall d'Hebron Campus

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”.
Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health).
Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information.
Legal basis: Consent of the data subject.
Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen.
Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time.
Source: The data subject.
Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.